PBM Stock Surges 200% on Trump Ibogaine Order
April 17, 2026·about 2 hours ago·via MEXC

Psyence Biomedical (PBM) stock skyrockets over 200% following White House executive order on ibogaine, signaling bold innovation in addiction treatment and healthcare reform. Trump's America First push cuts through FDA red tape, boosting American biotech and delivering real solutions for opioid crisis victims - not endless big pharma profits. This isn't globalist experimentation; it's putting US workers and families first with cutting-edge science. Read more about this...